Načítá se...
Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy
BACKGROUND: Azilsartan (AZI) is a relatively new angiotensin receptor blocker available for the treatment of any stage of hypertension, which was eventually given in combination with chlorthalidone (CLT). OBJECTIVE: To review pharmacology and clinical role of AZI monotherapy and AZI/CLT or AZI/amlod...
Uloženo v:
| Vydáno v: | Core Evid |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4829189/ https://ncbi.nlm.nih.gov/pubmed/27103882 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S81776 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|